Biomarker Study in Patients With Herpes Zoster

Keimyung University

Status: Completed

Conditions: Herper Zoster

Treatments: Procedure: Herpes zoszter (acute)with inter vention

Study type: Interventional

Funder types: Other

Identifiers

NCT05685797

2022-09-016

Details and patient eligibility

About

Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin) in peripheral blood of participants with herpes zoster.

Full description

Sudden and electrick shooting sensation of face is an important clinical feature of herpes zoster. The severe and excruciating nature of pain intensity associated with herpes zoster can impair the physical and psychosocial well-being of the patient, however, pathophysiologic mechanism of herpes zoster still remains unclear.

Recentrly, there have been a few studies suggesting biomarker levels in the blood and CSF level, however, further study is required to elucidate the action mechanism.

Up to 90% of patients can achieve pain reduction using medical therapy alone. However, 10% -15% of herpes zoster cases demonstrate a minimal response to medication with various side effects. Radiofrequency thermocoagulation (RFT) of the trigeminal ganglion is an alternative treatment option for patients who are poor candidates for microvascular decompression or show serious side effects to medication. Recent study revealed that RFT of the trigeminal ganglion resulted in Barrow Neurological Institute (BNI) pain scale I or II in 71.7% of patients, with a median time to recurrence of 36 months.

Although patients experience significant pain relief after RFT, it is uncertain whether inflammatory cytokine and neurocytokine (CGRP, substance P, VIP) are reduced.

Enrollment: 30 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with NRS more than 4
• patients who failed medical treatment
• patients showing severe adverse reaction with medication

Exclusion criteria

• Patients showing allergic reaction to local anesthetics
• Patients with coagulation abnormality

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

30 participants in 2 patient groups

herpes zoster (acute) patients with intervention

Experimental group

Description:

Patients with herpes zoster receiving 2 times of nerve block

Treatment:

Procedure: Herpes zoszter (acute)with inter vention

patients with chronic herpes zoster receiving 2 times of nerve block

Experimental group

Description:

Patients with herpes zoster receiving 2 times of nerve block

Treatment:

Procedure: Herpes zoszter (acute)with inter vention